Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07849309) titled 'Real-World Incidence of Intraocular Inflammation Following Intravitreal Treatment With Aflibercept 8 mg' on Sept. 24.

Study Type: Observational

Primary Sponsor: Copenhagen University Hospital, Rigshospitalet

Condition: Intraocular Inflammation Intravitreal Injections

Intervention: Drug: Aflibercept (Eylea)

Recruitment Status: Not recruiting

Date of First Enrollment: April 20, 2026

Target Sample Size: 3690

Countries of Recruitment: Denmark

To know more, visit https://clinicaltrials.gov/study/NCT07849309

Published by HT Digital Content Services with permission from Health Daily Digest....